205
Participants
Start Date
November 30, 2006
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
PB127 for Injectable Suspension
"Stages 1 \& 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 \& 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
University of Pittsburgh Cardiovascular Institute, Pittsburgh
Alfieri Cardiology, Newark
The Cleveland Clinic Foundation, Cleveland
University of Chicago Medical Center, Chicago
St. Louis University Medical Center, St Louis
Cardiovascular Consultants, Kansas City
The Center for Cardiovascular Studies Kramer and Crouse Cardiology, Shawnee Mission
Midwest Cardiology Associates, Overland Park
Seton Healthcare Network Brackenridge Hospital, Austin
Austin Heart, Austin
Long Beach VA Medical Center Cardiology Division, Long Beach
University of California San Diego Division of Cardiology, San Diego
Oregon Health Sciences University, Portland
Inland Cardiology, Spokane
Northwest Cardiovascular Research Institute Spokane Cardiology, Spokane
Androscoggin Cardiovascular Associates, Auburn
Lead Sponsor
Point Biomedical
INDUSTRY